The Hague, Netherlands:
The coronavirus vaccine developed by AstraZeneca and Oxford University, which was approved in the UK on Wednesday, is unlikely to receive a green light in the European Union next month, according to the European Medicines Agency (EMA).
The regulator, charged with overseeing the approval of vaccines in the EU before they can be marketed, approved the Pfizer BioNTech vaccine on December 21st. He is expected to make a decision on Moderna’s vaccine on January 6th.
“The EMA has not yet been given a formal marketing authorization, so the EMA Committee on Medicinal Products for Human Use has not yet set a timeline for the approval of the AstraZeneca-Oxford Stitch,” the Amsterdam-based agency told AFP.
The regulator’s deputy director, Noel Walthion, told the Belgian newspaper Het Nieuwsblad on Tuesday that a possible approval in January was “unlikely”, the agency confirmed on Tuesday.
The AstraZeneca-Oxford vaccine is currently undergoing an “ongoing review” which allows the EMA to review safety and efficacy data when it is released, even before the manufacturer submits a formal application for approval.
This process speeds up the evaluation of an application for authorization once it has been submitted, according to the EMA.
The UK on Wednesday became the first country in the world to approve the vaccine, which is cheaper to manufacture and easier to store and transport than the Pfizer BioNTech batch.
For the EU countries, it is up to the European Commission in Brussels to give the green light after approval by the EMA.
The vaccinations with the Pfizer BioNTech vaccine started on the weekend in the 27-person block.
(Except for the headline, this story was not edited by GossipMantri staff and posted from a syndicated feed.)